Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21144113 | 0.90 | GPR119 (0.54) | GPR119CHEK2STSNPBWR1MCHR1 | |
| SCHEMBL21606920 | 0.88 | GPR119 (0.51) | GPR119CHEK2P2RX3P2RX2STS | |
| SCHEMBL21604529 | 0.88 | CHEK2 (0.49) | GPR119CHEK2P2RX3P2RX2 | |
| SCHEMBL21606956 | 0.85 | GPR119 (0.50) | GPR119CHEK2NPBWR1MCHR1 | |
| SCHEMBL24091438 | 0.82 | GPR119 (0.60) | GPR119CHEK2STSNPBWR1MCHR1 | |
| SCHEMBL29913326 | 0.81 | GPR119 (0.54) | GPR119CHEK2P2RX3P2RX2STS | |
| SCHEMBL6121103 | 0.81 | GPR119 (0.50) | GPR119NPBWR1MCHR1 | |
| SCHEMBL23311671 | 0.81 | GPR119 (0.54) | GPR119CHEK2P2RX3P2RX2STS | |
| SCHEMBL9894022 | 0.81 | GPR119 (0.50) | GPR119P2RX3P2RX2STSNPBWR1 | |
| SCHEMBL21606981 | 0.81 | GPR119 (0.46) | GPR119CHEK2NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GPR119 1166/4885CHEK2 575/4885P2RX3 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.